To include your compound in the COVID-19 Resource Center, submit it here.

Paratek Pharmaceuticals Inc, Transcept deal

Infectious disease company Paratek will reverse-merge with Transcept in a stock deal. Transcept will issue Paratek stockholders about 167.5 million Transcept shares, valued at $333.3 million based on Transcept’s close of $1.99 on June 30, before the deal was announced. Paratek stockholders are expected to own about 89.6%

Read the full 488 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE